<h1>CCI Seeks Public Comments on Sun Pharma and Ranbaxy Merger; Potential Market Competition Concerns u/s 29(2.</h1> The Competition Commission of India (CCI) is seeking public comments on the proposed merger between Sun Pharmaceuticals Industries Limited and Ranbaxy Laboratories Limited, as the merger may adversely affect market competition. As per Section 29(2) of the Competition Act, 2002, the companies must publish merger details in major newspapers and on their websites. The CCI invites written comments, objections, or suggestions from affected parties within fifteen working days of publication, to be sent to the Secretary of the CCI in New Delhi.